Paper Details

  1. Home
  2. Paper Details

Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).

Author: BallinariGianluca, BarbourSally Y, CoxDavid, MorrowGary R, SchwartzbergLee, ThornMichael D

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Palonosetron, a 5HT3 receptor antagonist, was more effective than older drugs at preventing chemotherapy-induced nausea and vomiting.
Paper Details　
Original Abstract of the Article :
Preventing chemotherapy-induced nausea and vomiting (CINV) is integral to treatment success in patients with cancer. This analysis was undertaken to assess the relative efficacy and safety of palonosetron versus older 5HT3 RAs in preventing CINV associated with moderately or highly emetogenic chemot...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889920/

データ提供：米国国立医学図書館（NLM）

Palonosetron: A Strong Contender for Preventing Chemotherapy-Induced Nausea and Vomiting

Chemotherapy, a powerful weapon against cancer, can often come with unwelcome side effects, particularly nausea and vomiting. This study compares the efficacy and safety of palonosetron, a newer antiemetic, to older 5HT3 receptor antagonists (5HT3 RAs) in preventing chemotherapy-induced nausea and vomiting (CINV). The authors conducted a pooled analysis of phase III clinical trials, examining the effectiveness of palonosetron versus ondansetron, dolasetron, and granisetron. Their findings suggest that palonosetron is a formidable contender, offering greater efficacy and safety in preventing CINV associated with moderately or highly emetogenic chemotherapy.

Palonosetron: A Triumph Over Nausea and Vomiting

This analysis reveals that palonosetron consistently outperforms older 5HT3 RAs in preventing CINV. The authors' findings demonstrate that palonosetron offers a more effective and safer option for managing this distressing side effect of chemotherapy.

Combating Chemotherapy Side Effects: A New Era of Antiemetics

This research highlights the advancements in antiemetic therapies, offering a new era of hope for those undergoing chemotherapy. It's like finding a refreshing oasis in the vast desert of cancer treatment side effects, offering a more effective and tolerable way to manage this challenging symptom. Palonosetron represents a significant step forward, improving the quality of life for cancer patients and allowing them to better cope with the challenges of their treatment.

Dr.Camel's Conclusion

This pooled analysis provides compelling evidence for the efficacy and safety of palonosetron in preventing chemotherapy-induced nausea and vomiting. The authors' findings offer a valuable roadmap for optimizing antiemetic therapies, allowing us to better navigate the challenges of cancer treatment and provide greater support to patients.

Date :
  1. Date Completed 2014-08-06
  2. Date Revised 2022-03-11
Further Info :

Pubmed ID

24141698

DOI: Digital Object Identifier

PMC3889920

Related Literature

Article Analysis
・Effects of dolasetron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.